Founded in Monmouth Junction, New Jersey, Gyros is a pioneering organization specializing in automated micro-immunoassays for therapeutic protein development. Their core mission is to enhance the efficiency of immunoassay processes, significantly reducing the time required for assay optimization from weeks to days. Gyros offers the Gyrolab platform, an automated and versatile analytical tool that supports various applications such as serology assays, PK assays, and biomarker analysis. Their market focus includes biopharmaceutical companies and research institutions aiming to streamline therapeutic protein development.

Gyros has garnered attention for its innovative technology and significant impact on the biopharmaceutical industry. Notable affiliated individuals and investors include key figures in biotech and pharmaceutical sectors who recognize the value of Gyros' contributions. The company's achievements include widespread adoption of the Gyrolab platform, which has set new standards for assay transfer ease and process development efficiency. Overall, Gyros has made a substantial impact by accelerating therapeutic protein development and clinical evaluations, thereby fostering advancements in medical research and treatment.